USANA Health Sciences (NYSE:USNA) Stock Rating Upgraded by StockNews.com

USANA Health Sciences (NYSE:USNA) was upgraded by equities researchers at StockNews.com from a “buy” rating to a “strong-buy” rating in a report issued on Thursday.

Separately, DA Davidson cut their price target on shares of USANA Health Sciences from $38.00 to $35.00 and set a “neutral” rating on the stock in a research note on Wednesday, October 23rd.

USANA Health Sciences Stock Performance

Shares of USNA stock opened at $33.38 on Thursday. USANA Health Sciences has a one year low of $33.28 and a one year high of $54.81. The firm’s 50 day moving average price is $37.96 and its 200-day moving average price is $40.47. The firm has a market cap of $636.22 million, a P/E ratio of 11.80, a P/E/G ratio of 1.25 and a beta of 0.89.

USANA Health Sciences (NYSE:USNA) last released its quarterly earnings results on Tuesday, October 22nd. The company reported $0.56 EPS for the quarter, topping analysts’ consensus estimates of $0.49 by $0.07. The company had revenue of $200.22 million for the quarter, compared to analysts’ expectations of $208.45 million. USANA Health Sciences had a return on equity of 10.64% and a net margin of 6.30%. During the same period in the prior year, the firm earned $0.59 earnings per share. As a group, research analysts predict that USANA Health Sciences will post 2.45 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director Gilbert A. Fuller sold 675 shares of USANA Health Sciences stock in a transaction dated Monday, November 4th. The stock was sold at an average price of $37.71, for a total value of $25,454.25. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 0.33% of the company’s stock.

Institutional Trading of USANA Health Sciences

Large investors have recently made changes to their positions in the company. SG Americas Securities LLC acquired a new position in USANA Health Sciences during the 2nd quarter worth approximately $340,000. Bank of New York Mellon Corp grew its stake in shares of USANA Health Sciences by 5.6% during the second quarter. Bank of New York Mellon Corp now owns 97,375 shares of the company’s stock worth $4,405,000 after purchasing an additional 5,205 shares in the last quarter. Panagora Asset Management Inc. increased its holdings in USANA Health Sciences by 143.1% in the second quarter. Panagora Asset Management Inc. now owns 28,881 shares of the company’s stock valued at $1,307,000 after buying an additional 16,999 shares during the last quarter. Rhumbline Advisers raised its stake in USANA Health Sciences by 7.1% in the second quarter. Rhumbline Advisers now owns 36,486 shares of the company’s stock valued at $1,651,000 after buying an additional 2,425 shares in the last quarter. Finally, Pzena Investment Management LLC boosted its position in shares of USANA Health Sciences by 24.4% during the 2nd quarter. Pzena Investment Management LLC now owns 976,633 shares of the company’s stock worth $44,183,000 after acquiring an additional 191,289 shares in the last quarter. 54.25% of the stock is currently owned by hedge funds and other institutional investors.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.